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Background: Single-agent pemetrexed is a treatment for recurrent non-squamous non-small cell lung
cancer (NSCLC) that provides limited benefit. Preclinical studies showed promising synergistic effects when
the mammalian target of rapamycin (mTOR) inhibitor sirolimus was added to pemetrexed.
Methods: This was a single-institution phase I/II study of pemetrexed in combination with sirolimus. The
primary endpoint for the phase I was to determine the maximum tolerated dose (MTD) and safety of the
combination. The primary endpoint for the phase II portion was to determine the overall response rate at
the MTD. Key eligibility criteria included recurrent, metastatic NSCLC, ECOG performance status of
0–2, and adequate organ function. Sirolimus was administered orally daily after an initial loading dose, and
pemetrexed was given intravenously on day 1 of every 21-day cycle.
Results: Forty-two patients with recurrent, metastatic NSCLC were enrolled, 22 in phase I and 20
in phase II. The MTD was pemetrexed 500 mg/m2 every 3 weeks, and sirolimus 10 mg on day 1, and
3 mg daily thereafter. Treatment-related adverse events (AEs) occurred in 38 (90.5%) patients. The most
common grade 3–4 treatment-related AEs were lymphopenia (31%) and hypophosphatemia (19%). Two
treatment-related deaths occurred due to febrile neutropenia and infection, respectively. Among 27 total
patients treated at the MTD, 6 (22.2%) had a partial response (PR), 12 (44.4%) had stable disease (SD) and
5 (18.5%) had progressive disease. Median progression-free survival (PFS) was 18.4 weeks (95% CI: 7.0–29.4).
Conclusions: The combination of pemetrexed and sirolimus is active in heavily-pretreated NSCLC
(ClinicalTrials.gov Identifier: NCT00923273).
Keywords: Lung cancer; pemetrexed; phase I/II, sirolimus; thymidylate synthase (TS)
Submitted Nov 17, 2018. Accepted for publication Apr 16, 2019.
doi: 10.21037/tlcr.2019.04.19
View this article at: http://dx.doi.org/10.21037/tlcr.2019.04.19

a

Current address: Hematology/Medical Oncology, Parkview Cancer Institute, Fort Wayne, IN, USA.

b

Current address: Lombardi Comprehensive Cancer Center, Georgetown University, Washington DC, USA.

c

Current address: AstraZeneca, One MedImmune Way, Gaithersburg, MD, USA.

© Translational lung cancer research. All rights reserved.
This document is a U.S. government work and
is not subject to copyright in the United States.

Transl Lung Cancer Res 2019;8(3):247-257 | http://dx.doi.org/10.21037/tlcr.2019.04.19

Komiya et al. Pemetrexed plus sirolimus in NSCLC

248

Introduction
Non-small cell lung cancer (NSCLC) accounts for the
highest cancer mortality in the US, killing more than
150,000 people annually (1). Approximately 30–40% of
NSCLC patients present with metastatic disease where
only systemic therapy has an impact on survival (2).
Once patients relapse after initial treatment, they have
limited therapeutic options that can modestly improve
survival. At the time this study was conducted, approved
chemotherapies in this setting included single-agent
pemetrexed and docetaxel (3,4).
Discovery of driver oncogenes such as epidermal growth
factor receptor (EGFR) led to development of tyrosine
kinase inhibitors, benefiting patients with activating
mutations or translocations. However, the population
with driver mutations for which tyrosine kinase inhibitors
are available is small in Western countries (20% in
Caucasians), limiting its application to a subset of patients,
and development of resistance is an inevitable consequence
of treatment (5). More recently, a greater understanding
of tumor immunology has resulted in the identification of
immune checkpoints that can be therapeutically targeted to
enhance anti-tumor immune responses. Antibodies targeting
the programed death-1 (PD-1) and its ligand (PD-L1) (e.g.,
nivolumab, pembrolizumab, and atezolizumab), have been
approved for treatment of metastatic NSCLC (6). Although
durable benefit is observed in patients responding to
treatment, a relatively small number of patients develop an
objective response to immune checkpoint inhibition therapy
and escape mechanisms ultimately result in development of
resistance in most cases. Despite the promise and benefit
of targeted therapies and immunotherapies in selected
NSCLC populations, newer forms of treatment are needed
to expand the efficacy of standard agents such as pemetrexed
in patients with advanced NSCLC.
Our group has previously demonstrated that the Aktmammalian target of rapamycin (mTOR) pathway is
frequently activated in NSCLC, and its activation is
associated with a worse clinical outcome (7,8). Several
agents related to rapamycin targeting mTOR signaling
are clinically available. Temsirolimus (Torisel ® ) and
everolimus (Afinitor®) are approved in the first and secondline treatment of renal cell carcinoma, respectively (9,10).
Sirolimus (Rapamune ®) is indicated for post-transplant
immunosuppression, with a well described toxicity
profile (11). Preclinical studies from our group showed
a synergistic anti-cancer effect between pemetrexed and
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sirolimus in vitro and in vivo. Sirolimus blocks pemetrexedinduced thymidylate synthase (TS) activation in vivo,
which may further enhance activity of pemetrexed (12).
The addition of mTOR inhibitors such as sirolimus may
therefore synergistically cause anti-tumor effects.
The combination of mTOR inhibitors with pemetrexed
has previously been evaluated in small phase I trials and
found to be safe and tolerable (13,14). To our knowledge
this is the largest trial for the phase II portion reported
to date to determine the safety and clinical activity of
pemetrexed in combination with an mTOR inhibitor in
previously treated NSCLC (13,14).
Methods
Study design and treatment
The study was approved by the National Cancer Institute
(NCI) Institutional Review Board (IRB), conducted at the
NCI, and registered in a clinical trial registry (ClinicalTrials.
gov Identifier: NCT00923273). All patients signed the
written informed consent approved by the NCI IRB.
The primary objective of the phase I portion of the study
was to determine the maximum tolerated dose (MTD) of
pemetrexed and sirolimus in combination in patients with
NSCLC. The secondary objectives were to analyze the
pharmacokinetics (PK) of both agents, and mTOR pathway
inhibition in peripheral blood mononuclear cells (PBMC).
A standard 3+3 dose escalation design was used for the
phase I portion (15). Cohorts of 3 patients were enrolled at
each dose level (Table S1), and an additional 3 patients were
enrolled if one or more of the first 3 patients developed dose
limiting toxicity (DLT). Doses of pemetrexed and sirolimus
were based on cohort assignment. Starting doses of both
pemetrexed and sirolimus were below FDA-approved doses.
The MTDs were based on the tolerability observed
during the first 4 weeks of treatment, although several
patients required dose reduction at later cycles. The MTDs
were defined as the highest doses at which less than two
out of six patients experienced DLT. The primary objective
of phase II component was to determine the activity of
the combination at the MTD. The objective response rate
(ORR) was evaluated by study investigators using RECIST
v1.0 (16).
Prior to the first dose of pemetrexed on cycle 1 day 8
all patients received a loading dose and one-week lead-in
course of once daily oral sirolimus. Patients who tolerated
the lead-in period then continued the same dose of daily
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sirolimus and received pemetrexed infusion intravenously
every three weeks at the assigned doses. Each treatment
cycle consisted of three weeks except cycle 1. Standard
premedications including corticosteroids, folic acid and
vitamin B12 were administered to all patients. After several
patients in the phase II portion with a high steady-state
sirolimus level developed significant toxicities, the protocol
was amended. Sirolimus dose reduction was mandated if a
trough sirolimus level exceeded 15 ng/mL at any subsequent
cycles.
Dose reduction to the next lower dose level was
also mandated if patients in either phase I or II portion
developed DLT during any cycle of the treatment. Patients
with tumor response of stable disease (SD) or better as
defined by RECIST1.0 continued the treatment until
disease progression or intolerable toxicities.
Patient eligibility
Eligible patients were aged 18 or older, and had
histologically confirmed NSCLC that had relapsed after
at least one standard chemotherapeutic regimen. Patients
must have had measurable disease for the phase II portion
of the study. Patients must also have had an expected
survival time of at least 3 months, an ECOG performance
status of 0–2, and adequate organ function as determined
by absolute neutrophil count (ANC) ≥1,500/mL; platelets
≥100,000/mL; total bilirubin <1.5× upper limit of
institutional normal (ULN); AST (SGOT) <2.5× ULN;
ALT (SGPT) <2.5× ULN; serum triglycerides <2.5× ULN;
serum cholesterol <300 mg/dL; estimated creatinine
clearance as calculated using the MDRD equation11 must
be ≥60 mL/min/1.73 m2. Tumor EGFR mutation status was
not required for study eligibility because genomic analysis
of the tumor was not routine practice at the time of study
initiation.
Study assessment
Adverse events (AEs) were evaluated and graded by
N C I C o m m o n Termi no l o g y Cri teri a fo r Adver se
Events (CTCAE Version 3.0) (17), and were monitored
throughout the study and for up to 28 days after the
last pemetrexed or sirolimus dose. DLTs were defined
as any grade 4 hematologic toxicity (except grade 4
lymphopenia or grade 4 neutropenia with duration of
7 days or less), febrile neutropenia (neutrophil count
<1,000 cells/mm3 and temperature ≥38.5 ℃), grade 3 or 4
© Translational lung cancer research. All rights reserved.

hypercholesterolemia (>400 mg/dL or 10.34 mmol/L) or
grade 3 or 4 hypertriglyceridemia (>5× ULN) in spite of
treatment with HMG-CoA reductase inhibitors, grade 3 or
4 diarrhea that has not resolved to grade 2 within 24 hours
and grade 1 within 48 hours of anti-diarrhea agents, grade
3 or 4 pneumonitis, grade 3 or 4 mucositis, grade 3 nausea
or vomiting that did not resolve to grade 2 within 24 hours
and grade 1 within 48 hours of anti-emetic agents.
At the dose level identified as the MTD, up to 30
subjects were required for the phase I portion of the trial
(5 levels with a maximum of 6 patients per level). If dose
level 5 was reached and the MTD had not been established,
dose level 5 would be used as the dose for subjects enrolling
on the phase II portion of the study. Phase II portion was
divided into pemetrexed-naïve and pre-treated groups, and
objective response rates were assessed separately. Patients
enrolled in the MTD level of phase I portion were added
onto phase II portion for both safety and efficacy analysis.
Tumor re-staging by CT imaging was conducted at
screening, after completion of cycle 2, and every six weeks
thereafter, and radiographic response was evaluated by
RECIST1.0. Body PET/CT imaging was performed at
baseline and completion of cycle 2. Patients who developed
DLTs or completed cycle 1 were considered evaluable for
AEs. Tumor responses were assessed on an intent-to-treat
basis.
On cycle 1 days 7 and 8, blood samples from phase I
patients were obtained as baseline and selected time points
after the administration of sirolimus and were analyzed for
sirolimus and pemetrexed levels. Blood samples for steadystate sirolimus level were drawn from both phase I and
II patients at baseline, weekly during cycle 1 and day 1 of
subsequent cycles.
Blood samples were collected at baseline, cycle
1 day 8, cycle 2 day 21 and subsequent every 2 cycles
for mTOR pathway analysis. Protein extracted from
PBMC was subsequently analyzed for mTOR pathway
inhibition (mTOR, P-S6K, 4E-BP1, P-S6, and Akt) by
immunoblotting (12). Suppression of TS was also evaluated
by western blotting.
Twenty-two patients were accrued on the phase I portion
of this trial. Table 1 contains the sirolimus and pemetrexed
doses for each dose level. Plasma concentrations of cycle
1 day 8 (C1D8) pemetrexed were measured using a
validated HPLC-MS/MS method with a calibration range
of 50–20,000 ng/mL. Sirolimus trough measurements were
independently analyzed from blood on C1D8.
A noncompartmental PK analysis of C1D8 pemetrexed
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Table 1 Patient characteristics
Clinical characteristics

Phase I

Phase II

Total

DL4 (P I/II)

22

20

42

27

57 [33–79]

62 [24–72]

62 [24–79]

61 [24–77]

11/11

10/10

21/21

13/14

Non-Sq

16

17

33

21

Sq

6

3

9

6

0–1

16

11

27

15

2

6

9

15

12

2 [1–4]

3 [1–7]

2 [1–7]

2 [1–7]

Prior pemetrexed

0

8

8

8

Pemetrexed naive

22

12

34

19

Prior EGFR-TKI

9

12

21

15

EGFR mutation (positive/tested)

4/13

3/19

7/32

5/25

Kras mutation (positive/tested)

3/14

7/20

10/34

8/26

ALK translocation (positive/tested)

0/3

0/15

0/18

0/18

Total No.
Median age [range]
Male/female
Histology

PS

Prior regimens median [range]

Non-Sq, non-squamous; Sq, squamous; PS, performance status; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor;
ALK, anaplastic lymphoma kinase; DL, dose level.

was performed on 20 patients using WinNonlin v5
( P h a r s i g h t C o r p , M o u n t a i n v i e w, C A , U S A ) w i t h
patients receiving either 375 mg/m 2 (n=6) or the FDA
recommended (18) dose of 500 mg/m 2 (n=14). The
maximum plasma concentration (C MAX ) was recorded
as observed values and the area under the plasmaconcentration time curve extrapolated to time infinity
(AUCINF) was calculated using the Linear Trapezoidal rule.
Statistics
Following a phase I cohort with up to 6 patients per dose
level, patients were enrolled in two cohorts depending
upon whether they were pemetrexed-naïve or had prior
pemetrexed. Both cohorts employed a Simon two-stage
phase II optimal design to evaluate the responses, with
alpha =0.10 and beta =0.10 in each.
In the pemetrexed-naïve cohort, the objective was to rule
out a 9% response rate (P0=0.09) in favor of a 34% response
rate (P1=0.34). The first stage would enroll 7 patients, and
if there were 0 responses, accrual would end. If 1 or more

© Translational lung cancer research. All rights reserved.

patients responded, accrual would continue until a total of
20 evaluable patients had been accrued. One to 3 responses
in 20 patients would have been considered inadequate while
4 or more of 20 with a response would be desirable. The
probability of early termination under the null hypothesis
was 52%.
In the cohort that received prior pemetrexed, the
objective was to rule out a 5% response rate (P0=0.05) in
favor of a 20% response rate (P1=0.20). The first stage
would enroll 12 patients, and if there were 0 responses,
accrual would end. If 1 or more patients responded, accrual
would continue until a total of 37 evaluable patients had
been accrued. One to 3 responses in 37 patients would have
been considered inadequate while 4 or more of 37 with
a response would be desirable. The probability of early
termination under the null hypothesis was 54%.
For PK analysis, the Wilcoxon rank sum test was used
to test the difference between parameters of interest in two
groups of patients. The Spearman correlation coefficient (r)
was used to determine the correlation between continuous
variables, and was interpreted by the following: strong
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association: |r|>0.7, moderate association: 0.5<|r|<0.7,
moderate to weak association: 0.3<|r|<0.5, and weak
association: |r|<0.3. Somers D was used to determine the
correlation between ordered categorical data and can be
interpreted similarly to Spearman’s correlation coefficient.
The Jonckheere-Terpstra trend test was used to test for a
trend between dose level and C1D8 sirolimus blood trough
concentration. All P values are two-tailed and unadjusted
for multiple comparisons.
Progression-free survival (PFS) was determined from the
on-study date until the date of death, date of progression,
or last follow-up; patients who died without progression
were also considered to be failures for this analysis. The
probability of PFS as a function of time was determined
by the Kaplan-Meier method. Fisher’s exact test was used
to determine the statistical significance of the difference
between two proportions.
Results
Patient characteristics
Between November 2008 and June 2012, 42 patients were
enrolled; 22 in phase I and 20 in the phase II portion.
Patient characteristics are listed in Table 1. Due to a slow
accrual rate, the study was prematurely terminated before
the accrual ceiling was reached.
Safety
The phase I dose escalation continued up to dose level 5
(pemetrexed 500 mg/m2, sirolimus 15 mg loading/5 mg
subsequent), at which one patient developed a DLT (grade
3 fatigue, Table 2), and two patients required dose reduction
at cycle 2. Therefore, the decision was made to enroll
4 more patients in dose level 4 where one patient developed
a DLT (grade 3 infection). Dose level 4 (pemetrexed 500
mg/m2, sirolimus 10 mg load/3 mg/day) was determined
to be the MTD, and all patients enrolled in the phase II
portion were initially treated at this dose level. However,
four of the first seven phase II patients developed significant
AEs. One patient developed grade 5 febrile neutropenia,
and three patients required dose reduction of sirolimus for
grade 3 or 4 nonhematologic toxicities (two patients with
pulmonary toxicities, one with hyponatremia). These four
patients had a steady-state sirolimus trough level higher
than 15 ng/mL, whereas only one of the remaining three
patients who tolerated DL4 had a high sirolimus level.

© Translational lung cancer research. All rights reserved.

Additional dose reduction of sirolimus was thereafter
mandated in the later part of phase II if patients had a
sirolimus trough level of 15 ng/mL or higher at any time
point.
Of 27 patients enrolled at the MTD/DL4 (7 in phase
I and 20 in phase II), 13 patients received at least 5 cycles
of the combination treatment (Table 2: treatment exposure
and dose reduction), and 20 patients completed at least first
cycle (Table 2). Twelve patients at all dose levels resulted in
a dose reduction at subsequent cycles (Table 2) due to AEs
(n=8) or high sirolimus trough level (n=4). Nevertheless,
none required further dose modification at DL3. The
majority (83.3%, 35 of 42) came off study due to disease
progression.
All AEs related to the study drugs (possible, probable
and definite) at all dose levels/phases are listed in Table 3.
The most common hematologic and nonhematologic AEs
at grade 3–4 were lymphopenia (31%), neutropenia (14%),
anemia (12%), and leukopenia (10%), hypophosphatemia
(19%), fatigue (14%), and hyperglycemia (10%). Two
patients receiving pemetrexed 500 mg/m2 and sirolimus
3 mg developed grade 5 neutropenia and infection. Both
patients developed AEs a few days after the first pemetrexed
infusion and had steady-state sirolimus levels higher than
15 ng/mL.
Clinical activity
A total of 27 patients were enrolled at the MTD/
recommended phase II dose (RP2D) and analyzed for
efficacy (Table 4, Figure 1A). Six (22.2%) patients achieved
a partial response, 12 (44.4%) had SD and 5 (18.5%) had
progressive disease. The overall response rate was 22.2%.
We observed clinical activity in two patients not expected
to respond to pemetrexed as a single-agent, such as a
patient who had been treated previously with pemetrexed
and progressed on it who achieved a PR as well as in a
patient with squamous histology. Tumor responses were
more frequent in pemetrexed naïve vs. those with prior
pemetrexed [5/19 (26.3%) vs. 1/8 (12.5%); P=0.63].
This indicates that the pemetrexed-naïve group reached
at least desirable response as defined in the methods
section, whereas efficacy in patients with prior exposure to
pemetrexed group was not adequately evaluated due to an
underpowered sample size.
Higher response rates were seen in and non-squamous
vs. squamous patients [5/21 (23.8%) vs. 1/6 (16.7%);
P=1.00] and EGFR-mutated patients vs. patients with no
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Table 2 Treatment exposure and dose reduction
Variables

Phase I

Phase II

Level 1

Level 2

Level 3

Level 4

Level 5

Level 4

n=4

n=3

n=3

n=7

n=5

n=20

0

0

0

1

1

NA

0

1

0

0

2

0

5

1

0

0

0

0

0

0

2

2

0

0

1

1

3

3

0

1

0

0

0

1

4

0

1

0

1

1

1

5–6

0

0

2

0

0

3

7–10

0

0

1

0

1

3

11–20

1

1

0

2

2

4

21+

0

0

0

1

0

0

Disease progression

4

3

3

5

5

14

Death of unknown cause

0

0

0

0

0

1

Voluntary withdrawal

0

0

0

0

0

2

AEs

0

0

0

1

0

3

Total

0

0

0

1

2

9

Due to AEs

0

0

0

1

2

5

Due to sirolimus trough >15 ng/mL

0

0

0

0

0

4

No.
DLT (phase I)
No. of completed cycles

Reason for discontinuation

Dose reduction in patients ≥1 cycle(s)

AEs, adverse events. Dose levels are described in detail in the Table S1.

EGFR mutations or unknown mutation status [3/5 (60%)
vs. 3/22 (13.6%); P=0.056]. When another efficacy analysis
for all patients (n=42) was performed, these trends were
maintained (Table S2). Survival analysis showed a median
PFS of 18.4 (95% CI: 7.0–29.4) weeks in patients at the
MTD (Figure 1B).
PK
Twenty of the twenty-two enrolled patients on the phase
I portion of this trial had evaluable data for PK analysis.
One patient on dose level 1 (taken off study due to brain
metastasis) and one patient on dose level 4 (taken off study
due to progressive disease) were not evaluable for PK
analysis.

© Translational lung cancer research. All rights reserved.

Pemetrexed administered at the 500 mg/m 2 dose level
exhibited a similar exposure and half-life (t 1/2) of 144.7
ug×h/mL and 2.79 h, respectively, as a previous report using
the same dose, where AUCINF and t1/2 were 158 ug×h/mL
and 2.62 h, respectively (19). There were no statistically
significant differences in half-life (P=0.97) or clearance
(P=0.72) between the two dose levels (Figure S1). However,
there was a statistical trend of increasing CMAX (P=0.041,
Figure S2A), but not AUCINF (P=0.31, Figure S2B).
When comparing C1D8 sirolimus trough blood
concentrations on each dose level, there is a clear increasing
trend with dose (Jonckheere-Terpstra trend test P=0.0013)
(Figure S3). To examine whether increasing sirolimus trough
levels were associated with pemetrexed PK, sirolimus trough
levels were plotted against pemetrexed CMAX and AUCINF
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Table 3 Treatment-related adverse events (AEs) at all levels (n=42, phase I/II)
Variables

All grades [%]

Grade 3–4 [%]

Leukopenia

14 [33]

4 [10]

Neutropenia

16 [38]

6 [14]

Lymphopenia

25 [60]

13 [31]

Anemia

21 [50]

5 [12]

Thrombocytopenia

17 [40]

3 [7]

Fatigue

19 [45]

6 [14]

Hypophosphatemia

16 [38]

8 [19]

Nausea/vomiting

16 [38]

1 [2]

Hyperglycemia

15 [36]

4 [10]

Hypomagnesemia

14 [33]

2 [5]

ALT

14 [33]

3 [7]

Hypercholesterolemia

9 [21]

0 [0]

Creatinine

9 [21]

0 [0]

Hypertriglyceridemia

8 [19]

0 [0]

Dyspnea

4 [10]

2 [5]

Infection

6 [14]

2 [5]

Grade 5 [%]

Hematologic

1 [2]

Nonhematologic

1 [2]

ALT, aspartate aminotransferase.

Table 4 Efficacy results at the MTD
Variables

Best overall response [%]†

Total

PFS (weeks)

PR

SD

PD

NE

median (95% CI)

Intent-to-treat

27

6 [22]

12

5

4

18.4 (7–29.4)

≥1 cycle

20

6 [30]

12

2

0

27.4 (14.1–44)

Non-squamous

21

5 [24]

9

4

3

19.4 (6.9–41)

Squamous

6

1 [17]

3

1

1

15.5 (5.9–55)

Prior pemetrexed

8

1 [13]

5

1

1

19.6 (2.9–43)

Pemetrexed naïve

19

5 [26]

7

4

3

16.9 (6.9–29.4)

Prior EGFR-TKI

15

5 [33]

7

3

0

19.7 (9.1–44)

EGFR WT/NA

22

3 [14]

12

3

4

17.8 (5.9–28)

EGFR mutant

5

3 [60]

0

2

0

43 (9.1–undefined)

Kras WT/NA

19

6 [32]

8

4

2

19.4 (9.1–43)

Kras mutant

8

0 [0]

4

1

2

12 [2–41]

†

, response percentages are displayed based on all patients, not restricted to those evaluable for response. EGFR, epidermal growth
factor receptor; TKI, tyrosine kinase inhibitor; WT, wild-type; NA, not analyzed; PR, partial response; SD, stable disease; PD, progressive
disease; NE, not evaluable; PFS, progression-free survival.
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Figure 1 Of the 27 patients at the MTD, seven developed progression (n=3), toxicities (n=3), or patient withdrawal (n=1) prior to
completion of cycle 1. Two patients clinically progressed before completion of initial re-staging. (A) RECIST % for best response in
evaluable patients who completed re-staging after 2 cycles (n=18). The dotted line indicates 30% reduction from the baseline. *, RECIST =0%;
blue bars, adenocarcinoma; red bars, squamous cell carcinoma; shaded bars, prior pemetrexed exposure +. (B) Progression-free survival (PFS)
in evaluable patients at the MTD (n=27). MTD, maximum tolerated dose.

(Figure S4). There were only moderate or weak correlations
between sirolimus trough levels and pemetrexed CMAX or
AUCINF. This suggests that increasing sirolimus levels are
not associated with pemetrexed PK.
Pharmacodynamics
Assessment for mTOR in PBMC was performed in a
total of 23 available patients. No inhibition on mTOR
signaling was observed at DL 1 or 2 (Figure S5A). P-S6K
and P-S6 were inhibited in response to sirolimus treatment
in patients treated at the MTD (Figures 2 and S5B,C).
Feedback activation of P-Akt, which is generally considered
as a resistance mechanism to mTOR-targeted therapies
such as rapamycin that only target mTORC1 complexes
was not observed in the majority of patients. To determine
if concurrent administration of sirolimus can influence
pemetrexed-induced activation of TS at the MTD, western
blotting with protein derived from PBMC was performed
in a total of 18 patients who were treated at the MTD.
In contrast to our in vitro and in vivo mouse study, where
sirolimus blocked activation of TS in cells/tumor tissue (14),
TS activation was only temporarily affected by concurrent
treatment of sirolimus (Figure 2).
Discussion
In this phase I/II study we demonstrate the tolerability
and clinical activity of a combination of pemetrexed with
sirolimus in patients with recurrent NSCLC. Pemetrexed
is approved for first line therapy of non-squamous NSCLC
© Translational lung cancer research. All rights reserved.

as part of a platinum doublet and is frequently used for
treatment of recurrent non-squamous NSCLC. However,
response rates remain low and the survival benefit is modest.
Various attempts to combine pemetrexed with other
cytotoxic drugs have not shown any benefit over pemetrexed
alone (20-23). This group and others have shown that
the Akt-mTOR signaling cascade is frequently activated
in NSCLC cells, indicating that TORC1 inhibitors such
as sirolimus could be potential therapies for NSCLC
(7,8). Previously published in vitro and in vivo studies also
showed enhanced anti-cancer efficacy of the combination
of pemetrexed and sirolimus over either agent alone in
NSCLC (12). Based on these preclinical observations, the
current study was designed to evaluate the combination of
pemetrexed and sirolimus in recurrent NSCLC.
The best overall response for intent-to-treat patients at
pemetrexed 500 mg/m2/sirolimus 10 mg load/3 mg/day was
22% which appears to be higher than historical data from
single-agent pemetrexed studies in unselected patients in
the literature (4). Other regimens using pemetrexed with
mTOR inhibitors yielded relatively low response rates of
0–11% (13,14). The response rate was higher in patients
with EGFR mutation. Other prior studies also reported
higher response rate to single-agent pemetrexed in EGFRmutated or ALK-rearranged NSCLC (24-27). The reason
for better response in theses populations is unclear.
What mechanisms might underlie the combination of
pemetrexed and sirolimus? Preclinical and clinical studies
indicated that squamous carcinoma has high TS expression
which is one of molecular targets of the anti-folate agent
pemetrexed (26). However, it has also been shown that a
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Pemetrexed: 500 mg/m2
Sirolimus: 3 mg daily
12–09
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Figure 2 Biomarker modulation in patients at the MTD. Protein
derived from PBMC were obtained at baseline, cycle 1 day 8, and
cycle 2 day 21 for immunoblotting of mTOR signaling (p-S6K,
p-S6, 4E-BP1 and p-Akt) and Thymidylate synthase (TS). A
representative western blotting result is shown. MTD, maximum
tolerated dose; PBMC, peripheral blood mononuclear cell.

low level of TS expression is associated with high antitumor activity of pemetrexed (26-29). This suggests that the
clinical responsiveness to pemetrexed in squamous NSCLC
might be improved if additional agents were able to
decrease TS expression. Our group has been investigating
potential mechanism of action for synergistic effect of
pemetrexed and sirolimus in preclinical models. Preclinical
studies suggest that sirolimus blocks pemetrexed-induced
TS activation in tumor tissue (12), which in turn is expected
to enhance sensitivity to pemetrexed according to the
multiple preclinical studies (27-29). This clinical trial
intended to test this hypothesis by correlative studies. It
was not feasible to analyze tumor tissue for TS activation;
however, contrary to the preclinical in vitro and in vivo
study, analysis in PBMC showed that an inhibitory effect of
sirolimus on TS activation was observed but only temporary
(Figure 2). Sustained suppression of TS level in tumor tissue
might be required to further enhance anti-tumor effect
of pemetrexed. Although these observations still need to
be validated, inhibition of TS activation is a mechanism

© Translational lung cancer research. All rights reserved.

that may support the observation of activity with the
combination in this phase I/II study.
The combination of pemetrexed and sirolimus in
this study was relatively well tolerated, and appeared to
have no new safety concern when compared with other
combinations of pemetrexed with an mTOR inhibitor
except as described below (13,14). Although grade 3 and
higher neutropenia frequently occurred in other studies
using pemetrexed and mTOR inhibitors (37–60%) (13,14),
it was observed in 14% of participants in this study. Other
hematological and nonhematological grade 3–4 events such
as dyspnea (5%) were also less frequently or similarly seen
in this study. As described earlier, early deaths possibly
attributable to the study drugs occurred in two patients
(4.8%), whereas six deaths on study were reported in
another study using pemetrexed and everolimus in 43
NSCLC patients (13). The two treatment-related deaths in
the first 7 patients in phase II led to the modification of the
design to incorporate monitoring of trough sirolimus level.
Subsequent 20 patients did tolerate well without grade
5 toxicities. Careful monitoring of myelosuppression is
strongly recommended for future studies.
Conclusions
The findings from this study indicate that the combination
of pemetrexed and sirolimus is feasible and active in patients
with heavily pretreated, advanced NSCLC. Additional
clinical trials would be required to optimize dosing
schedules to minimize toxicity and maximize benefit and
identify the role of this combination in the context of the
evolving therapeutic landscape of NSCLC.
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Supplementary
Table S1 Dose levels
Pemetrexed (iv), mg/m2

Sirolimus (po), mg load/mg/day

−1

186

1.5/0.5

1

375

3/1

2

375

6/2

3

500

6/2

4

500

10/3

5

500

15/5

Dose level

Table S2 Efficacy in all dose levels
Variables

Total

Best overall response [%]†

PFS (weeks)‡

PR

SD

PD

NE

Median (95% CI)

Intent-to-treat

42

9 [21]

19

7

7

18.4 (10–28.9)

Non-squamous

33

8 [24]

16

4

5

19.6 (13.7–41)

Squamous

9

1 [11]

3

3

2

8 (1.4–26.9)

Prior pemetrexed

8

1 [13]

5

1

1

19.5 (2.9–43)

Pemetrexed naïve

34

8 [24]

14

6

6

18.3 (9.1–28.9)

Prior EGFR TKI

21

7 [33]

10

3

1

19 (13.7–43)

EGFR WT/NA

35

6 [17]

17

5

7

18.3 (8.9–26.9)

EGFR mutant

7

3 [43]

2

2

0

43.5 (9.1–undefined)

Kras WT/NA

32

9 [28]

13

6

5

19 (10–29.4)

Kras mutant

10

0 [0]

6

1

2

17.6 [2–41]

†

‡

, response percentages are displayed based on all treated patients, not restricted to those evaluable for response; , PFS based on up to
41 patients with follow-up data. EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; WT, wild-type; NA, not analyzed;
PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable; PFS, progression free survival.

A

B
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Figure S1 Difference in half-life (A) and clearance (B) between pemetrexed doses. There is a clear increasing trend with dose (JonckheereTerpstra trend test P=0.0013) when comparing C1D8 sirolimus trough blood concentrations on each dose level.
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Figure S2 Difference in CMAX (A) and AUCINF (B) between pemetrexed doses.
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Figure S3 Increased C1D8 sirolimus trough levels with dose.
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Figure S4 Lack of correlation between sirolimus trough levels and CMAX (A) or AUCINF (B).
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Dose level 2
Pemetrexed: 375 mg/m2
Sirolimus: 2 mg daily

Dose level 1
Pemetrexed: 375 mg/m2
Sirolimus: 1 mg daily
A
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B

C A
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B
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A

*
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B

C A
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*
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p-S6K
(T389)
p-S6
(S235/6)
4E-BP1
p-Akt
(S473)
TS
B-actin

B

Dose level 4 (MTD)
Pemetrexed: 500 mg/m2
Sirolimus: 3 mg daily
23–10
A

B

24–10
C A

B

25–10
C A

B

27–11
C

A

*

B

31–11
C A

B

32–11
C A

B

33-11
C A

B

C

*

p-S6
(S235/6)
p-Akt
(S473)
TS

B-actin

34–11
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B

39–12
C A

B

C A

40–12
B

C A
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B C
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p-Akt
(S473)
TS
B-actin
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Figure S5 Biomarker analyses for additional patient samples at DL 1, 2, 4 and 5. (A) baseline; (B) cycle 1 day 8; (C) cycle 3 day 21. *, positive
control (H460 cells treated with pemetrexed). Modulation of mTOR pathway was not observed at DL 1 and 2.

